Gilead Sciences presents five-year Phase II ZUMA-5 trial results for Yescarta in relapsed non-Hodgkin lymphomas, showing a 90 ...
Galapagos' CAR-T therapy GLPG5101 shows promise but faces challenges with limited data, cash reserves, and competition in the ...
Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta®(axicabtagene ciloleucel) that demonstrate improved outcomes for people living with ...
Hosted on MSN8h
GILD Obtains Positive CHMP Opinion for Liver Disease DrugGilead Sciences, Inc. GILD announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European ...
These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...
Therefore, it is similar in principle to the approved CAR T-cell therapies used in cancer therapy, such as Kymriah and ...
There are two cell therapies approved in this patient setting, Johnson & Johnson’s Carvykti and Bristol Myers Squibb's Abecma ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the ...
Oswald: Down the Rabbit Hole announces that Tik-Tok fame creator & actress Nora Freetly has been cast in next year's horror ...
The drug could will offer a simpler alternative to third-line CAR-T therapies for DLBCL, namely Novartis’ Kymriah (tisagenlecleucel), Gilead Sciences’ Yescarta (axicabtagene ciloleucel), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback